Heart failure biomarker linked to rare genetic tumor-causing diseases

 By Sarah Marshall

Galectin-3, a protein that promotes cancer cell growth and is used as a biomarker for heart failure, has been linked to tumors observed in two rare genetic diseases.

Uniformed Services University (USU) and National Heart, Lung, and Blood Institute (NHLBI) researchers discovered that galectin-3 is produced by tumor cells in tuberous sclerosis complex (TSC) and lymphangioleiomyomatosis (LAM).

USU staff scientist Dr. Peter Klover was the first author on the study, published in eLife, that linked a heart failure biomarker to two rare genetic tumor-causing diseases, tuberous sclerosis complex and lymphangioleiomyomatosis. (Image credit: Sarah Marshall)

According to the Tuberous Sclerosis Alliance, “TSC is a genetic disorder that causes tumors to form in many different organs, primarily in the brain, eyes, heart, kidney, skin and lungs.” Women with TSC are highly susceptible to developing LAM, and LAM also occurs rarely in those without TSC.

LAM is a lung disease that typically attacks women “during the prime of their lives and is characterized by an abnormal growth of smooth muscle cells, especially in the lungs, lymphatic system and kidneys. Unregulated growth of these cells can lead to loss of lung function, accumulation of lymph rich-fluid in the chest and abdomen and growth of tumors in the kidneys,” according to The LAM Foundation.

Both TSC and LAM are caused by mutations in the TSC1 or TSC2 genes.

This slide shows the abnormalities in blood and lymphatic vessels caused by disruption of the Tsc2 gene. (Image credit: Dr. Thomas Darling)

Dr. Thomas Darling, professor and chair of Dermatology at USU, and Dr. Joel Moss, deputy branch chief of the Cardiovascular and Pulmonary Branch at NHLBI, and their team of researchers, worked with The American Genome Center at USU to closely examine molecular pathways affected by TSC2 mutation, and found that galectin-3 was elevated in tumors from patients with TSC or LAM. They found that serum levels of galectin-3 correlated with lung disease severity and with the presence of renal tumors. The researchers now believe this could help to assess treatment response in TSC and LAM and to detect cancers with mutations in TSC1 or TSC2.

First author Dr. Peter Klover, a senior research associate in USU’s Department of Dermatology, also examined mesenchymal cells – cells that form connective tissue and skin – and found that those which did not have the TSC2 gene reproduced aspects of TSC disease. This would be useful for finding new treatment modalities and markers of disease severity.

Ultimately, these findings have important implications for precision medicine approaches to treating other diseases associated with the loss of the TSC2 gene, helping to discover new treatments and other markers for disease diagnosis and prognosis.

The results were published in eLife July 11, 2017.

USU lab members who contributed to the paper, including (left to right, front row) Rajesh Thangapazham, Ji-an Wang, (back row) Thomas Darling, Shaowei Li, and Peter Klover (first author). (Image credit: Dr. Thomas Darling)